Corbus Pharmaceuticals Holdings (CRBP) Short term Debt (2015 - 2024)

Corbus Pharmaceuticals Holdings has reported Short term Debt for 5 years, with the latest figure at $12.8 million in Q1 2024.

• On a quarterly basis, Short term Debt rose 154.85% year-over-year to $12.8 million in Q1 2024; TTM through Mar 2024 was $12.8 million, a 154.85% increase from a year earlier, with the FY2023 full-year figure at $15.9 million, up 469.03% from the prior year.
• Short term Debt was $12.8 million for Q1 2024 at Corbus Pharmaceuticals Holdings, down from $15.9 million in the prior quarter.
• The five-year high for Short term Debt was $17.8 million in Q3 2023, with the low at $2.8 million in Q4 2022.
• Average Short term Debt over 4 years is $8.7 million, with a median of $7.2 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2023: Short term Debt fell 9.62% in 2022, then jumped 469.03% in 2023.
• Over 4 years, Short term Debt stood at $3.1 million in 2021, then slipped by 9.62% to $2.8 million in 2022, then surged by 469.03% to $15.9 million in 2023, then slipped by 19.76% to $12.8 million in 2024.
• The last three Short term Debt figures came in at $12.8 million (Q1 2024), $15.9 million (Q4 2023), and $17.8 million (Q3 2023), per Business Quant data.